Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S333.
doi: 10.21037/atm.2019.09.119.

Are we approaching a new era in the treatment of anemia of chronic kidney disease patients?

Francesco Locatelli  1 , Lucia Del Vecchio  1
Affiliations
Editorial

Are we approaching a new era in the treatment of anemia of chronic kidney disease patients?

Francesco Locatelli et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Prof. Locatelli is Member of an advisory Board of Amgen, GSK, Roche, Vifor Pharma and invited Speaker at meeting supported by Amgen, Astellas–Astra-Zeneca, GSK, Mitsubishi, Roche, Vifor pharma. Dr. Lucia Del Vecchio had been member of Advisory Boards for DOC, Roche, Astellas and invited speaker at meetings supported by DOC, Roche, Astellas, Vifor Pharma. She is national leader for the ASCEND-ND study supported by JSK.

Comment on

  • Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Chen N, et al. N Engl J Med. 2019 Sep 12;381(11):1001-1010. doi: 10.1056/NEJMoa1813599. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31340089 Clinical Trial.

Similar articles

See all similar articles

Cited by

References

    1. Del Vecchio L, Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert Opin Drug Saf 2016;15:1021-30. 10.1080/14740338.2016.1182494 - DOI - PubMed
    1. Parfrey PS. Erythropoietin-stimulating agents in chronic kidney disease: a response to hyporesponsiveness. Semin Dial 2011;24:495-97. 10.1111/j.1525-139X.2011.00949.x - DOI - PubMed
    1. Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008;3:193-9. 10.2215/CJN.02440607 - DOI - PubMed
    1. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:439-46. 10.1053/ajkd.2002.34881 - DOI - PubMed
    1. Locatelli F, Del Vecchio L, Marai P. Clinical experience with darbepoetin-alfa (Aranesp). Contrib Nephrol 2002;(137):403-7. 10.1159/000060268 - DOI - PubMed